ライフサイエンスコーパス: hepatitis B virus

1 cluding nonalcoholic fatty liver disease and hepatitis B virus.

2 rus (WHV), a hepadnavirus closely related to hepatitis B virus.

3 with human immunodeficiency virus (HIV) and hepatitis B virus.

4 osis and other chronic liver diseases due to hepatitis B virus (12.2 million) and hepatitis C virus (

5 C virus (10.4 million), liver cancer due to hepatitis B virus (9.4 million), rheumatic heart disease

6 ly recruits adaptive responses as opposed to hepatitis B virus and cancer-testis antigens.

7 The study of hepatitis B virus and development of curative antivirals

8 es in the longer term through the control of hepatitis B virus and hepatitis C virus infections by va

9 The prevalence of viral hepatitis (hepatitis B virus and hepatitis C virus) in migrants is

10 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral

11 confirm upregulation of Gal-9 on T cells in hepatitis B virus and HPV infections.

12 ent discoveries of contemporary genotypes of hepatitis B virus and parvovirus B19 in ancient human re

13 We also confirm suppression of hepatitis B virus and poliovirus by ARB.

14 on-Pfizer monkey virus), two hepadnaviruses (hepatitis B virus and woodchuck hepatitis virus), and an

15 pentavalent (diphtheria, tetanus, pertussis, hepatitis B virus, and Haemophilus influenzae type b), y

16 that can affect replication of retroviruses, hepatitis B virus, and hepatitis C virus (HCV).

17 ajor viral targets, i.e., hepatitis C virus, hepatitis B virus, and human immunodeficiency virus 1.

18 tomegalovirus, human immunodeficiency virus, hepatitis B virus, and neonatal herpes simplex virus, fr

19 la, influenza A, human immunodeficiency, and hepatitis B viruses are examined in the first section; t

20 ce the risk of environmental transmission of hepatitis B virus but also open up the possibility of te

21 retrotransposons, and other viruses such as hepatitis B virus, but can cause a mutator phenotype in

22 e show that cell-culture and patient-derived hepatitis B virus can establish persistent infection for

23 It is likely that the closely related hepatitis B virus capsid protein undergoes similar struc

24 Chronic hepatitis B virus carriers are at risk of developing fib

25 Hepatitis B virus causes chronic infections in 250 milli

26 ed a prolonged suppression of human and duck hepatitis B virus cccDNA transcription, which is associa

27 ned (1:1) HLA-B*5701-negative adults without hepatitis B virus co-infection to receive coformulated b

28 those with a human immunodeficiency virus or hepatitis B virus coinfection, and those treated with bo

29 age, gender, smoking status, hepatitis C and hepatitis B virus coinfection, group of exposure, nadir

30 model of hepatitis B: infectious transgenic hepatitis B virus composed of a complete virus plus a fo

31 pid, high yield and economical production of Hepatitis B Virus core (HBc) particles.

32 s associated with a similar modest change in hepatitis B virus core antigen polypeptide (HBcAg/p21) s

33 for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with dev

34 will likely be needed to achieve functional hepatitis B virus cure.

35 The hepatitis B virus deploys the hepatitis B virus X protei

36 (FISH)-based assay for the detection of duck hepatitis B virus (DHBV) cccDNA and HBV nuclear DNA in e

37 For the avian hepadnavirus duck hepatitis B virus (DHBV), CTD is dephosphorylated subseq

38 The peak levels of hepatitis B virus DNA and hepatitis B core-related antig

39 Serum qHBcrAg, qAnti-HBc, and hepatitis B virus DNA were obtained at TDF initiation an

40 gical response after hepatitis C, suppressed hepatitis B virus during treatment, and alcoholic and no

41 f viruses, including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, influenza virus, resp

42 New inhibitors of hepatitis B virus entry, replication, assembly, or secre

43 The management for occupational HIV or hepatitis B virus exposures includes postexposure prophy

44 istinct methylation events in the integrated hepatitis B virus genome.

45 In Asia, HCCs from patients with hepatitis B virus have been efficiently converted into P

46 valence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.

47 ered included 230 million people living with hepatitis B virus (HBV) and 52 million people living wit

48 Hepatitis B virus (HBV) and hepatitis C virus (HCV) caus

49 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infe

50 Hepatitis B virus (HBV) and hepatitis C virus (HCV) rema

51 uss common challenges to the burden posed by hepatitis B virus (HBV) and hepatitis C virus (HCV), to

52 Infections with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depe

53 er extensive mixed tailing in transcripts of hepatitis B virus (HBV) and human cytomegalovirus (HCMV)

54 ed viruses such as Epstein-Barr virus (EBV), hepatitis B virus (HBV) and human papilloma virus (HPV;

55 Patients co-infected with hepatitis B virus (HBV) and the human immunodeficiency v

56 tions and displays excellent potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV)

57 the details of assembly/release pathways of hepatitis B virus (HBV) are still unknown.

58 Tests to detect the presence and activity of hepatitis B virus (HBV) are the cornerstones of diagnosi

59 transferase 1 (PRMT1) only modestly increase hepatitis B virus (HBV) biosynthesis.

60 Hepatitis B virus (HBV) can transmit through needle shar

61 been used to track the assembly of the T = 4 hepatitis B virus (HBV) capsid in real time.

62 enchmarked by monitoring the assembly of the hepatitis B virus (HBV) capsid.

63 ices to analyze in real time the assembly of Hepatitis B Virus (HBV) capsids below the pseudocritical

64 The hepatitis B virus (HBV) causes acute and chronic liver i

65 Hepatitis B virus (HBV) causes chronic infection in an e

66 Hepatitis B virus (HBV) chronic infection affects up to

67 Hepatitis B virus (HBV) chronically infects 250 million

68 Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenof

69 HCV) with direct-acting antivirals (DAAs) in hepatitis B virus (HBV) coinfection can result in HBV re

70 -cell lymphotropic virus type 1 (HTLV-1) and hepatitis B virus (HBV) coinfection is high in certain I

71 rus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral th

72 HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with

73 characteristics and comorbidities to chronic hepatitis B virus (HBV) controls using propensity scores

74 Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serolog

75 tion state of the C-terminal domain (CTD) of hepatitis B virus (HBV) core or capsid protein is highly

76 Mutations in the hepatitis B virus (HBV) core promoter (CP) have been sho

77 Though the hepatitis B virus (HBV) core protein is an important par

78 tion efforts, their lack of activity against hepatitis B virus (HBV) could limit their global impact,

79 mes that are involved in the biosynthesis of hepatitis B virus (HBV) covalently closed circular (ccc)

80 tion and the factors involved.IMPORTANCE The hepatitis B virus (HBV) covalently closed circular (CCC)

81 Hepatitis B virus (HBV) covalently closed circular (CCC)

82 Hepatitis B virus (HBV) covalently closed circular (ccc)

83 The biosynthesis of hepatitis B virus (HBV) covalently closed circular DNA (

84 itis B surface antigen (HBsAg)-positive with hepatitis B virus (HBV) DNA concentration of less than 2

85 itis B e antigen, antibodies to hepatitis D, hepatitis B virus (HBV) DNA for hepatitis B surface anti

86 ified APOBEC deaminases as enzymes targeting hepatitis B virus (HBV) DNA in the nucleus thus affectin

87 The paucity of hepatitis B virus (HBV) DNA measurement in low-/middle-i

88 ith nucleos(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affe

89 nd 95%, 99%, 100%, and 100% had undetectable hepatitis B virus (HBV) DNA, respectively.

90 plantation, 39 (72%) patients had detectable hepatitis B virus (HBV) DNA, with a median of 4.5 log co

91 The management of hepatitis B virus (HBV) e antigen-positive viremic patie

92 Hepatitis B virus (HBV) encodes a multifunction reverse

93 We examined factors associated with hepatitis B virus (HBV) exposure among people who report

94 To evaluate how hepatitis B virus (HBV) genetic variation affected progr

95 r DNA (cccDNA) is the persistent form of the hepatitis B virus (HBV) genome in viral infection and an

96 Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C

97 o date, conflicting data exist as to whether hepatitis B virus (HBV) has the ability to induce innate

98 tion, and HBV-driven tumor growth.IMPORTANCE Hepatitis B virus (HBV) HBx protein plays a critical rol

99 screened 693 European and African shrews for hepatitis B virus (HBV) homologs to elucidate the enigma

100 Hepatitis B virus (HBV) immunization has been effectivel

101 dvice 1: Clinicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (incl

102 The basis for the persistence of hepatitis B virus (HBV) in hepatocytes, even in the pres

103 the basis for replication and persistence of hepatitis B virus (HBV) in the chronically infected live

104 e the establishment of a seronegative occult hepatitis B virus (HBV) infection (OBI) in a successfull

105 Hepatitis B virus (HBV) infection affects approximately

106 Hepatitis B virus (HBV) infection afflicts millions worl

107 Rare individuals can naturally clear chronic hepatitis B virus (HBV) infection and acquire protection

108 pies with novel mechanisms of action against hepatitis B virus (HBV) infection are being explored wit

109 Therapies for chronic hepatitis B virus (HBV) infection are urgently needed be

110 k Force (USPSTF) found antiviral therapy for hepatitis B virus (HBV) infection associated with improv

111 Antagonism of host immune defenses against hepatitis B virus (HBV) infection by the viral proteins

112 Hepatitis B virus (HBV) infection can be prevented throu

113 (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a melittin

114 resistance to IFN therapy.IMPORTANCE Chronic hepatitis B virus (HBV) infection continues to be a majo

115 ventions to tackle the huge global burden of hepatitis B virus (HBV) infection depends on improved in

116 Screening for hepatitis B virus (HBV) infection during pregnancy ident

117 Hepatitis B virus (HBV) infection has a global reach wit

118 iral compounds.The lack of models that mimic hepatitis B virus (HBV) infection in a physiologically r

119 he mechanism(s) of age-dependent outcomes of hepatitis B virus (HBV) infection in humans, we previous

120 s conducted to estimate the global burden of hepatitis B virus (HBV) infection in people living with

121 regarding the prevalence and distribution of hepatitis B virus (HBV) infection in U.S. Hispanics/Lati

122 Chronic hepatitis B virus (HBV) infection is a global public hea

123 Chronic hepatitis B virus (HBV) infection is a global public hea

124 Chronic hepatitis B virus (HBV) infection is a global public hea

125 Hepatitis B virus (HBV) infection is a major cause of ac

126 Chronic hepatitis B virus (HBV) infection is a major public heal

127 Chronic hepatitis B virus (HBV) infection is a major risk factor

128 Chronic hepatitis B virus (HBV) infection is a risk factor for h

129 Hepatitis B virus (HBV) infection is a serious public he

130 Chronic hepatitis B virus (HBV) infection is estimated to affect

131 Hepatitis B virus (HBV) infection is more common in Afri

132 Chronic hepatitis B virus (HBV) infection is partly responsible

133 A hallmark of chronic hepatitis B virus (HBV) infection is the functional impa

134 on or cirrhosis due to other causes, such as hepatitis B virus (HBV) infection or alcohol, remains un

135 Hepatitis B virus (HBV) infection persists because the v

136 he heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the complex ho

137 Acute hepatitis B virus (HBV) infection remains a frequent cau

138 Hepatitis B virus (HBV) infection remains a major global

139 gy for children with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknown.

140 Hepatitis B virus (HBV) infection represents a significa

141 Development Goals (SDGs) for elimination of hepatitis B virus (HBV) infection set ambitious targets

142 as functional cure) in patients with chronic hepatitis B virus (HBV) infection significantly reduces

143 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in chil

144 Patients with resolved hepatitis B virus (HBV) infection who are treated for he

145 ions have among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but little

146 e 257 million persons worldwide with chronic hepatitis B virus (HBV) infection, a leading causes of l

147 infection (LTBI), 63.5% were susceptible to hepatitis B virus (HBV) infection, and 31.0% had at leas

148 hough there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies are protec

149 nt of a treatment regimen for curing chronic hepatitis B virus (HBV) infection.

150 ng the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection.

151 rcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

152 n patients with current or prior exposure to hepatitis B virus (HBV) infection.

153 th metabolic risk factors, for patients with hepatitis B virus (HBV) infection.

154 age to care can reduce the burden of chronic hepatitis B virus (HBV) infection.

155 Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections can lead to cirrhosis

156 ing age in the United States, but changes in hepatitis B virus (HBV) infections have not been studied

157 substantial increase in the number of acute hepatitis B virus (HBV) infections in the United States.

158 patitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China remains uncl

159 Chronic hepatitis B virus (HBV) infections result in 887,000 dea

160 BACKGROUND & AIMS: Hepatitis B virus (HBV) infects hepatocytes, but the mec

161 Hepatitis B virus (HBV) integration has implications for

162 ra DNA (vh-DNA), generated from junctions of hepatitis B virus (HBV) integration in the HCC chromosom

163 Hepatitis B virus (HBV) is a leading cause of liver dise

164 Hepatitis B virus (HBV) is a leading cause of liver fail

165 iral and host proteins on HBV-DNA.IMPORTANCE Hepatitis B virus (HBV) is a major global health concern

166 Hepatitis B virus (HBV) is a major global health concern

167 Hepatitis B virus (HBV) is a major health problem worldw

168 Hepatitis B virus (HBV) is a major human pathogen, and a

169 plication-competent viral capsids.IMPORTANCE Hepatitis B virus (HBV) is a major human pathogen, and n

170 Its occurrence as a satellite virus of hepatitis B virus (HBV) is a singular case in animal vir

171 Hepatitis B virus (HBV) is a unique, tiny, partially dou

172 Hepatitis B virus (HBV) is an important but difficult to

173 h, particularly in sub-Saharan Africa, where hepatitis B virus (HBV) is an important risk factor.

174 virus (HDV) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progres

175 Hepatitis B virus (HBV) is endemic in sub-Saharan Africa

176 Hepatitis B virus (HBV) is the leading cause of hepatoce

177 Hepatitis B virus (HBV) is the major causative factor of

178 Hepatitis B virus (HBV) modulates microRNA (miRNA) expre

179 t with compensated cirrhosis associated with hepatitis B virus (HBV) or hepatitis C virus (HCV) infec

180 , we identified 35,356 patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infec

181 We examined the associations between hepatitis B virus (HBV) or hepatitis C virus (HCV) infec

182 ), most cases of which are related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

183 nct populations of hepatocytes infected with hepatitis B virus (HBV) or only harboring HBV DNA integr

184 -replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

185 Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients

186 Hepatitis B virus (HBV) reactivation has been reported i

187 Hepatitis B virus (HBV) reactivation in hepatitis B surf

188 )ide analogue (NA) is recommended to prevent hepatitis B virus (HBV) reactivation in hepatitis B surf

189 Immunosuppressants can induce hepatitis B virus (HBV) reactivation; however, informati

190 ate cotransporting polypeptide (NTCP) as the hepatitis B virus (HBV) receptor enabled researchers to

191 an integral component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantat

192 esponse and Organ failure) for patients with Hepatitis B Virus (HBV) related acute-on-chronic liver f

193 Hepatitis B virus (HBV) remains a major global health pr

194 With a yearly death toll of 880,000, hepatitis B virus (HBV) remains a major health problem w

195 Despite an effective vaccine, hepatitis B virus (HBV) remains a major public health th

196 eraction mechanisms for achieving an optimal hepatitis B virus (HBV) replication have been largely un

197 Hepatitis B Virus (HBV) replication in hepatocytes is re

198 79), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated

199 plays a role in the epigenetic regulation of hepatitis B virus (HBV) replication.

200 Persistent or chronic infection with the hepatitis B virus (HBV) represents one of the most commo

201 We have evaluated the ability of hepatitis B virus (HBV) RNA and hepatitis B core-related

202 presents a clinically pragmatic approach to hepatitis B virus (HBV) screening and management.

203 pies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) status.

204 ers (NAPs) inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles.

205 REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhanci

206 PXL are more active against alphaviruses and hepatitis B virus (HBV) than ZAPS and ZAPM and elucidate

207 New hepatitis B virus (HBV) therapies are expected to have b

208 Smoking interacts with hepatitis B virus (HBV) to increase the risk of hepatoce

209 is a host restriction factor that suppresses hepatitis B virus (HBV) transcription.

210 chromosomes 5/6 complex (Smc5/6) suppresses hepatitis B virus (HBV) transcription.

211 mary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide cli

212 Here, the CTD from the human hepatitis B virus (HBV) was found to be dephosphorylated

213 Hepatitis B virus (HBV) X protein, HBx, interacts with a

214 cquiring human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

215 f 47,591 adults wait-listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatiti

216 Hepatitis B virus (HBV), belonging to Hepadnaviridae fam

217 role of the transcriptional template of the hepatitis B virus (HBV), covalently closed circular DNA

218 Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalc

219 entified or confirmed clonal integrations of hepatitis B virus (HBV), human papillomavirus (HPV), Eps

220 Viral hepatitis, and particularly hepatitis B virus (HBV), is an important disease because

221 -residing pathogens, Schistosoma mansoni and hepatitis B virus (HBV), is barely understood.

222 is in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD, and alcoholic liver dise

223 th infections by either hepatitis A virus or hepatitis B virus (HBV), or a noninfectious cause for th

224 Here, using mutational analyses of hepatitis B virus (HBV), we found that Hsp90 stimulates

225 B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increas

226 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-associated cirrhosis and HBV-ass

227 (MTA1) was correlated with poor prognosis of hepatitis B virus (HBV)-associated hepatocellular carcin

228 Hepatitis B virus (HBV)-encoded X protein (HBx) plays a

229 to exclude and confirm advanced fibrosis in hepatitis B virus (HBV)-human immunodeficiency virus (HI

230 We have sampled healthy and hepatitis B virus (HBV)-infected human livers to probe f

231 disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer (NK) and

232 cellular carcinoma (HCC) is most striking in hepatitis B virus (HBV)-related cases.

233 the first proteogenomic characterization of hepatitis B virus (HBV)-related hepatocellular carcinoma

234 apeutic approaches to augment the endogenous hepatitis B virus (HBV)-specific T cell response in CHB

235 Activated and hepatitis B virus (HBV)-specific T cells, particularly t

236 device for the quantitative detection of the hepatitis B virus (HBV)-the major cause of liver cirrhos

237 antiviral activity of AdrA was addressed in hepatitis B virus (HBV)-transgenic and adenovirus-associ

238 different stages of chronic coinfection with hepatitis B virus (HBV).

239 antiviral potential that has been applied to hepatitis B virus (HBV).

240 cy virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV).

241 he US are living with chronic infection with hepatitis B virus (HBV).

242 verse transcriptase (RT) activity of HIV and hepatitis B virus (HBV).

243 incidence/1000 patient-years was 49.3 among hepatitis B virus (HBV)/hepatitis C virus (HCV) coinfect

244 compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also signify

245 ased on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surfac

246 sfusion-transmitted infectious agents (TTIs; hepatitis B virus [HBV], HIV, human T-cell lymphotropic

247 Hepatitis B viruses (HBVs), which are enveloped viruses

248 ed were more frequently from older, heavier, hepatitis B virus (HCV)+, and more comorbid donors (P <

249 our understanding of the mechanisms by which hepatitis B virus, hepatitis C virus, alcohol, fatty liv

250 re found in the sera from patients with AIH, hepatitis B virus, hepatitis C virus, and nonalcoholic s

251 nfections (human immunodeficiency virus-1/2, hepatitis B virus, hepatitis C virus, human T-cell lymph

252 eterminants of the failed immune response to hepatitis B virus in patients with chronic infection.

253 FNalpha was confirmed in HEV gt1, but not in Hepatitis B Virus infected animals.

254 an guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide

255 y 247 million people are living with chronic hepatitis B virus infection (CHB), and the development o

256 A cross-sectional analysis of prevalence of hepatitis B virus infection (HBV) among rural couples wa

257 aried among low fruit intake (14 provinces), hepatitis B virus infection (seven provinces), smoking (

258 d the hepatitis B vaccine birth dose and the hepatitis B virus infection rate was 4 times lower.

259 ypes and several disease outcomes, including hepatitis B virus infection(5-7), graft-versus-host dise

260 naive and HLA-B*5701 negative, did not have hepatitis B virus infection, and had an estimated glomer

261 sity control, immunizing populations against hepatitis B virus infection, and screening for colorecta

262 immune dysfunction in patients with chronic hepatitis B virus infection, immunotherapy strategies in

263 Among individuals with hepatitis B virus infection, liver-related mortality dec

264 process that occurs only in patients with an hepatitis B virus infection.

265 with HIV infection are at increased risk for hepatitis B virus infection.

266 B vaccine is an effective measure to prevent hepatitis B virus infection.

267 fic T-cell immunity in patients with chronic hepatitis B virus infection.

268 and obesity; 12.5% (95% CI: 10.6-14.3%) for hepatitis B virus infection; 29.1% (95% CI: 23.6-34.5%)

269 copies per mL); HLA-B*5701-negative; had no hepatitis B virus infection; screening genotypes showing

270 Fewer than 1% of chronic hepatitis B virus infections per year are cured with ant

271 c kidney disease), and hepatitis C virus and hepatitis B virus infections.

272 For the discovery of hepatitis B virus integration sites from probe capture d

273 les with targeting peptides derived from the hepatitis B virus large envelope protein (HBVpreS) to sp

274 9 HDV-infected patients, 25 individuals with hepatitis B virus monoinfection and 18 healthy controls.

275 inovirus [n = 5], and parechovirus [n = 2]), hepatitis B virus (n = 10), cytomegalovirus (n = 9), Eps

276 Other positive viral detections included hepatitis B virus (n = 2), human pegivirus 1 (n = 2), Ep

277 Formation of the hepatitis B virus nucleocapsid is an essential step in t

278 The increased risk of HCC in patients with hepatitis B virus or adeno-associated virus type 2 infec

279 arcinomas (HCCs) from patients infected with hepatitis B virus or adeno-associated virus type 2, due

280 Chronic hepatitis B virus or hepatitis C co-infection was allowe

281 Patients with co-infection (hepatitis B virus or HIV infection), evidence of decompe

282 ce antigen and 13.4% had past infection with hepatitis B virus (positive anti-HBcore).

283 lly regulates several direct target genes of hepatitis B virus protein X (HBx), a viral co-factor.

284 Hepatitis B virus reactivation is a newly identified saf

285 Hepatitis B virus reactivation, defined as an abrupt inc

286 titis, Wilson disease, Budd-Chiari syndrome, hepatitis B virus reactivation, inborn errors of metabol

287 g the study, age-standardized mortality from hepatitis B virus-related extrahepatic complications inc

288 transfer of T cells engineered to express a hepatitis B virus-specific (HBV-specific) T cell recepto

289 axis, mother-to-child transmission (MTCT) of Hepatitis B Virus still occurs in approximately 2-5% of

290 yme as signal amplifier for determination of hepatitis B virus surface antigen (HBsAg).

291 of 3.3 x 10(8) particles/mL was obtained for hepatitis B virus T = 4 capsids with a 1.3 muL sample.

292 on coverage and greater lifetime exposure to hepatitis B virus than US-born women.

293 epatitis delta virus (HDV) is a satellite of hepatitis B virus that increases the severity of acute a

294 epatitis delta virus (HDV) is a satellite of hepatitis B virus that increases the severity of liver d

295 m to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of ma

296 nation, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms.

297 in Egypt (1054 [84%] of 1251 patients), and hepatitis B virus was the leading cause in the other Afr

298 Other STIs, except hepatitis B virus, were also more prevalent among HIV-in

299 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as a suppressor of hos

300 d by therapeutic targeting of HBx.IMPORTANCE Hepatitis B virus X protein (HBx) is a promising drug ta